

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 May 2007 (10.05.2007)

PCT

(10) International Publication Number  
**WO 2007/052023 A2**

(51) International Patent Classification: **Not classified**

[GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

(21) International Application Number:

PCT/GB2006/004075

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:

1 November 2006 (01.11.2006)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PI, PT, RO, RS, RU, SC only): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PI, PT, RO, RS, RU, SC only*): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (*for MG only*): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): LUKER, Timothy



A2

3

2007/052023

52023

(54) Title: NOVEL COMPOUNDS

WO


(57) Abstract: The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

## NOVEL COMPOUNDS

The present invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

EPA 1 170 594 discloses methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2, a ligand for orphan receptor CRTH2. GB 1356834 discloses a series of compounds said to possess anti-inflammatory, analgesic and antipyretic activity. It has been found that certain phenoxyacetic acids are active at the CRTH2 receptor, and as a consequence are expected to be potentially useful for the treatment of various respiratory diseases, including asthma and COPD.

In a first aspect the invention therefore provides compound of formula (I) or a carboxylic acid bioisostere thereof:



in which:

V is  $\text{CR}^1\text{R}^2$ ,  $\text{CR}^1\text{R}^2\text{-CR}^1\text{R}^2$  or V is  $\text{S(O)}_n\text{CR}^1\text{R}^2$  (where n is 0, 1 or 2),  $\text{NR}^{11}\text{CR}^1\text{R}^2$ ,  
20  $\text{CCR}^1\text{R}^2$ ,  $\text{CR}^1\text{R}^2\text{C}$  or  $\text{CR}^1\text{CR}^2$ ;

$\text{R}^1$  and  $\text{R}^2$  independently represent a hydrogen atom, halogen,  $\text{C}_2\text{-C}_6$  alkenyl,  $\text{C}_2\text{-C}_6$  alkynyl,  $\text{C}_3\text{-C}_7$  cycloalkyl or a  $\text{C}_{1-6}$  alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen,  $\text{C}_3\text{-C}_7$  cycloalkyl,  $\text{NR}^9\text{R}^{10}$ ,  $\text{OR}^8$ ,  $\text{S(O)}_n\text{R}^7$  (where n is 0, 1 or 2);

25 or


R<sup>1</sup> and R<sup>2</sup> together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR<sup>11</sup> and itself optionally substituted by one or more C<sub>1</sub>-C<sub>3</sub> alkyl or halogen;

W is hydrogen, halogen, cyano, nitro, SO<sub>2</sub>R<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, OR<sup>8</sup>, or C<sub>1-6</sub>alkyl, the latter being optionally substituted by one or more substituents independently selected from halogen, OR<sup>8</sup> and NR<sup>7</sup>R<sup>8</sup>, S(O)<sub>n</sub>R<sup>5</sup> where n is 0, 1 or 2.

R<sup>3</sup> is one or more substituents independently selected from hydrogen, halogen, CN, nitro, SO<sub>2</sub>R<sup>7</sup>, OR<sup>8</sup>, SR<sup>7</sup>, SOR<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, CONR<sup>9</sup>R<sup>10</sup>, NR<sup>9</sup>R<sup>10</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>7</sup>, NR<sup>11</sup>CO<sub>2</sub>R<sup>7</sup>, NR<sup>11</sup>COR<sup>7</sup> or C<sub>1-6</sub>alkyl, the latter being optionally substituted by one or more substituents independently selected from halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> where n is 0, 1 or 2;

X represents a bond, or C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted by one or more substituents independently selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl the latter being optionally substituted by one or more substituents independently selected from halogen, OR<sup>6</sup> and NR<sup>7</sup>R<sup>8</sup>, S(O)<sub>n</sub>R<sup>5</sup> where n is 0, 1 or 2;

Y represents a diamine of the following type:-



R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen, SO<sub>2</sub>R<sup>7</sup>, C(O)R<sup>7</sup>, CO<sub>2</sub>R<sup>7</sup> and C<sub>1</sub>-C<sub>6</sub> alkyl, the latter being optionally substituted by one or more substituents independently selected from aryl, heteroaryl, halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> where n is 0, 1 or 2;

R<sup>4</sup> and R<sup>5</sup> are joined together or one of R<sup>4</sup> and R<sup>5</sup> is joined onto P or Q to form a saturated heterocyclic 3-10 membered ring with, 1 or 2 endocyclic nitrogen atoms;

P and Q independently represent, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by one or more substituents independently selected from (=O), halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2), C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl or heteroaryl (the latter two being optionally substituted by one or more substituents independently selected from halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, CONR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> where n is 0, 1 or 2);

Z represents a bond, (CR<sup>12</sup>)n-C(O), (CR<sup>12</sup>)n-S(O)n, C(O)(CR<sup>12</sup>)n, or S(O)<sub>2</sub>(CR<sup>12</sup>)n, S(O)<sub>2</sub>N(CR<sup>12</sup>)n, where n= 0, 1 or 2;.

HET represents aryl or heteroaryl;

R<sup>6</sup> represents one or more substituents independently selected from hydrogen, halogen, CN, nitro, COR<sup>7</sup>, CO<sub>2</sub>R<sup>8</sup>, SO<sub>2</sub>R<sup>7</sup>, OR<sup>8</sup>, SR<sup>8</sup>, SOR<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, CONR<sup>9</sup>R<sup>10</sup>, NR<sup>9</sup>R<sup>10</sup>, NR<sup>8</sup>SO<sub>2</sub>R<sup>7</sup>, NR<sup>8</sup>CO<sub>2</sub>R<sup>8</sup>, NR<sup>8</sup>COR<sup>7</sup>, NR<sup>8</sup>CONR<sup>9</sup>R<sup>10</sup>, NR<sup>8</sup>SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, aryl, heteroaryl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, CN, OR<sup>8</sup>, NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2), CONR<sup>9</sup>R<sup>10</sup>, NR<sup>8</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup> and NR<sup>8</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>7</sup> represents a C<sub>1</sub>-C<sub>6</sub> alkyl, an aryl or a heteroaryl group all of which may be optionally substituted by halogen atoms, OR<sup>8</sup>, NR<sup>14</sup>R<sup>15</sup>;

R<sup>8</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>, alkyl, an aryl or a heteroaryl group all of which may be optionally substituted by halogen atoms, OR<sup>8</sup>, NR<sup>14</sup>R<sup>15</sup>;

R<sup>9</sup> and R<sup>10</sup> independently represent hydrogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup> and NR<sup>14</sup>R<sup>15</sup>, S(O)<sub>n</sub>R<sup>6</sup> (where n = 0,1 or 2), CONR<sup>7</sup>R<sup>8</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>5</sup>;

or

R<sup>9</sup> and R<sup>10</sup> together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)<sub>n</sub> (where n = 0,1 or 2), NR<sup>13</sup>, and itself optionally substituted by halogen or C<sub>1-3</sub> alkyl;

R<sup>11</sup> represents a hydrogen atom, C(O)R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl an aryl or a heteroaryl group (the latter three can be optionally substituted by halogen);

R<sup>12</sup> represents one or more from hydrogen, or a C<sub>1-6</sub>alkyl group, the latter being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, NR<sup>14</sup>R<sup>15</sup>, OR<sup>8</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2);

R<sup>13</sup> represents hydrogen, C<sub>1-4</sub> alkyl, -COC<sub>1</sub>-C<sub>4</sub> alkyl, COYC<sub>1</sub>-C<sub>4</sub>alkyl where Y is O or NR<sup>7</sup>; and

R<sup>14</sup> and R<sup>15</sup> independently represent hydrogen, C<sub>1-4</sub> alkyl


30 OR

R<sup>14</sup> and R<sup>15</sup> together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected

from O, S(O)<sub>n</sub> (where n = 0,1 or 2), NR<sup>13</sup>, and itself optionally substituted by halogen or C<sub>1-3</sub> alkyl;

and pharmaceutically acceptable salts thereof.

It is to be understood that the group -CO<sub>2</sub>H, as used herein, includes carboxylic acid bioisosteres. This is a term familiar to medicinal chemists and refers to functional groups which have similar acid-base characteristics to a carboxylic acid group. Well known carboxylic acid isosteres include, but are not limited to, the following groups:



10 Examples of monocyclic saturated rings as defined for Y include piperazine, alkyl substituted piperazine (such as methyl, ethyl or propyl piperazine), piperazinone, imidazolidine, homopiperazine, aminopyrrolidine, aminoazetidine and aminopiperidine.

Examples of aryl include phenyl and naphthyl.

15 Heteroaryl is defined as a 5-7 member aromatic ring or can be 6,6- or 6,5-fused bicyclic ring optionally containing one or more heteroatoms selected from N, S and O.

The bicyclic ring may be linked through carbon or nitrogen and may be attached through the 5 or 6 membered ring and can be fully or partially saturated. Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan, isoxazole, pyrrole, isothiazole and azulene, naphthyl, indene, quinoline, isoquinoline, indole, indolizine,

20 benzo[b]furan, benzo[b]thiophene, 1H-indazole, benzimidazole, benzthiazole, benzoxazole, purine, 4H-quinolizine, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, pteridine, quinolone and 1,2-methylenedioxy benzene.

In the context of the present specification, unless otherwise indicated the groups aryl and heteroaryl can be optionally substituted by R<sup>6</sup>.

25 In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched.

Heterocyclic rings as defined for R<sup>14</sup> and R<sup>15</sup> means saturated heterocycles, examples include morpholine, thiomorpholine, azetidine, imidazolidine, pyrrolidine, 30 piperidine and piperazine.

Preferably V is CR<sup>1</sup>R<sup>2</sup>, CR<sup>1</sup>R<sup>2</sup>-CR<sup>1</sup>R<sup>2</sup>, CCR<sup>1</sup>R<sup>2</sup> or CR<sup>1</sup>R<sup>2</sup>C, more preferably V is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>.

Preferably W is hydrogen or halogen, more preferably W is halogen, most preferably chloro.

5 Preferably R<sup>1</sup> and R<sup>2</sup> are independently hydrogen.

Preferably R<sup>3</sup> is hydrogen.

Preferably X is CH<sub>2</sub>.

Preferably the group Y (together with the two nitrogen atoms to which it is attached) is piperazine, which can be optionally substituted by C<sub>1-4</sub> alkyl.

10 Preferably the group Z is SO<sub>2</sub>, SO<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>, more preferably SO<sub>2</sub>CH<sub>2</sub> or C(O)CH<sub>2</sub>.

Preferably HET is aryl, or heteroaryl, more preferably HET is phenyl.

15 Preferably R<sup>6</sup> is hydrogen or one or more substituents selected from halogen, hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl (optionally substituted by one or more halogen atoms), alkoxy (alkyl group is optionally substituted by halogen atoms). More preferably R<sup>6</sup> is one of the substituents exemplified herein.

Preferred compounds of the invention include:

Sodium 3-(2-{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl) propanoate;

3-(2-{[(3S)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl}-4-chlorophenyl)propanoic

20 acid;

Sodium3-(4-chloro-2-{[(3S)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl}phenyl)propanoate;

3-(4-chloro-2-{[(3S)-3-methyl-4-(phenylacetyl)piperazin-1-yl]methyl}phenyl) propanoic acid;

25 3-[4-chloro-2-({(3S)-3-methyl-4-[(4-methylbenzyl)sulfonyl]piperazin-1-yl}methyl)phenyl]propanoic acid;

3-[4-chloro-2-({(3S)-3-methyl-4-[(3-methylbenzyl)sulfonyl]piperazin-1-yl}methyl)phenyl]propanoic acid;

3-[4-chloro-2-({(3S)-3-methyl-4-[(2-methylbenzyl)sulfonyl]piperazin-1-yl}methyl)phenyl]propanoic acid;

(2-{[(3S)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl}phenyl)acetic acid;

(4-chloro-2-{[(3S)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl}phenyl)acetic acid;

{4-chloro-2-[((3*S*)-3-methyl-4-{{4-(trifluoromethyl)phenyl}acetyl}piperazin-1-yl)methyl]phenyl}acetic acid;

[4-chloro-2-({(3*S*)-4-[(4-methoxyphenyl)acetyl]-3-methylpiperazin-1-yl}methyl)phenyl]acetic acid;

5 [4-chloro-2-({(3*S*)-4-[(2,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl)phenyl]acetic acid;

[4-chloro-2-({(3*S*)-4-[(3,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl)phenyl]acetic acid;

(2-{{(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl}methyl}-4-chlorophenyl) acetic acid;

10 [4-chloro-2-({(3*S*)-4-[(4-chlorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl)phenyl]acetic acid;

(4-chloro-2-{{(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl}methyl}phenyl)acetic acid;

[4-chloro-2-({(3*S*)-4-[(4-fluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl)phenyl]acetic acid;

15 [4-chloro-2-({(3*S*)-3-ethyl-4-[(4-fluorophenyl)acetyl]piperazin-1-yl}methyl)phenyl]acetic acid;

[4-chloro-2-({(3*S*)-4-[(4-chlorophenyl)acetyl]-3-ethylpiperazin-1-yl}methyl)phenyl]acetic acid;

20 2-(2-{{(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl}methyl}-4-chlorophenyl)-N-(methylsulfonyl)acetamide


and pharmaceutically acceptable salts thereof.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and  
25 mixtures thereof also form an aspect of the present invention.

The compound of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or  
30 procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups in the starting reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 3rd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1999).


Compounds of formula (I) can be prepared by hydrolysis of a compound of formula 10 (II):



(II)

in which  $\text{R}^{15}$  is methyl, ethyl or *tertiary* butyl, and can be removed under acidic or basic conditions for example by stirring in trifluoroacetic acid or dilute sodium hydroxide 15 in a suitable solvent such as dichloromethane, THF or methanol.  $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^6, \text{W}, \text{X}, \text{Y}$  and  $\text{Z}$  are as defined in compounds of formula (I) or protected derivatives thereof. Compounds of formula (II) are novel and form an additional part of the invention.

Compounds of formula (II) are prepared from compounds of formula (III) as described in Scheme 1.



Scheme 1


in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>15</sup>, P, Q, W, X, Y and Z are as defined in compounds of formula (II) or protected derivatives thereof.

When Z is SO<sub>2</sub>, or C(O) the compounds of formula (III) are reacted with sulfonyl chlorides or acid chlorides of formula (IV) in which L=Chlorine. The reaction is carried out in the presence of a base such as triethylamine, aqueous sodium hydrogen carbonate or potassium carbonate in a suitable organic solvent such as dichloromethane. When Z is alkyl compounds of formula (III) are reacted with alkyl chlorides using a suitable base such as triethylamine or sodium hydride in an organic solvent such as DMF or DCM.

When L=OH and Z = C(O) the reaction is carried out using a coupling reagent such as HATU in a suitable organic solvent such as DMF, DCM or NMP.

Compounds of formula (IV) are commercially available or can be prepared readily by those skilled in the art.


Compounds of formula (III) can be prepared from compounds of formula (V) by reacting with a diamine compound of formula (VI), by a coupling reaction in a suitable organic solvent for example THF, DMF or dichloromethane in the presence of a base such as triethylamine, potassium carbonate or the like;




in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>15</sup>, P, Q, V, W, and X are as defined in compounds of formula (II) or protected derivatives thereof. L<sup>1</sup> is a suitable leaving group such as mesylate or halogen.

The diamine compound of formula (VI) is monoprotected as compounds of formula (VIa) with a suitable amine protecting group such as BOC (tert-butyl carbonyl). This protecting group is subsequently removed under acidic conditions, for example TFA.

Compounds of formula (VIa) where the amine is monoprotected with the BOC protecting group are commercially available or may be protected by reacting compounds of formula (VI) with BOC anhydride in presence of a base for example, triethylamine in a suitable organic solvent such as dichloromethane:




15 in which R<sup>4</sup>, R<sup>5</sup>, P and Q, are as defined in compounds of formula (II). Certain  
compounds of formula (VIIa) are prepared from compounds of formula (VIb):



in which P<sup>2</sup> is a suitable amine protecting group, such as trityl. R<sup>4</sup>, R<sup>5</sup>, P and Q, are  
as defined in formula (I) or protected derivatives thereof. The trityl protecting group can  
selectively be removed by reacting with acid such as dilute HCl in a suitable organic  
solvent such as ethanol.


Compounds of formula (VIb) can be formed as outlined in Scheme 2:



Scheme 2

in which R<sup>4</sup>, R<sup>5</sup>, P, Q, and P<sup>2</sup> are as defined previously for compounds of formula (I) or protected derivatives thereof. P<sup>2</sup> is defined as for compounds of formula (VIb).

Compounds of formula (V), in which V is CCR<sup>1</sup>R<sup>2</sup> where R<sup>1</sup> and R<sup>2</sup> are hydrogen can be synthesised as outlined in Scheme 3:




Scheme 3

in which R<sup>3</sup> and W are as defined for compounds of formula (I) or protected derivatives thereof. L<sup>2</sup> is defined as for compounds of formula (V).

The hydroxyl group is converted to a leaving group preferably triflate using a suitable reagent, such as phenyl triflimate in the presence of a base such as triethylamine in a suitable organic solvent, suitably DMF. This intermediate then undergoes a Heck

reaction with an acrylate, such as methyl acrylate. The alkene moiety and the aldehyde are both reduced using hydrogenation conditions, suitably catalysed by platinum on charcoal. The resulting hydroxy methyl group is converted to a suitable leaving group by reacting with methane sulfonyl chloride in dichloromethane in the presence of a base such as triethylamine. A mixture of both chloro compound and mesylate (V) is obtained. The mixture can be separated or used directly to react with compounds of formula (VI).

Compounds of formula (V) in which V is  $\text{CH}_2\text{COOH}$  can be synthesised as outlined in Scheme 4:



10

Scheme 4


in which W and  $\text{R}^3$  are as outlined for compounds of formula (I) or protected derivatives thereof.  $\text{L}^2$  is defined as for compounds of formula (V).

The benzoic acid starting material is converted to the alcohol using a reducing agent, preferably, borane in a suitable organic solvent such as THF. The alcohol is then halogenated using a suitable chlorinating agent such as thionyl chloride in the presence of DMF in a solvent such as DCM; subsequent reaction with sodium or potassium cyanide gives the nitrile. The nitrile is then hydrolysed in aqueous potassium hydroxide at elevated temperature, preferably 100 °C. At this stage the acid can be esterified using standard procedures, such as stirring with trimethylsilyl chloride in methanol.

The aryl iodide (VII) can undergo a carbonylation reaction to form the acid by reacting with sodium formate and acetic anhydride and palladium catalysis. Preferred catalyst is *bis*(dibenzylideneacetone)palladium (0), in a suitable organic solvent such as DMF at elevated temperatures, preferably 80 °C. The acid is reduced to the benzyl alcohol 5 using borane as described earlier. The resulting alcohol is activated by mesylation or halogenation using standard procedures known by those skilled in the art. When the compound is mesylated using methane sulfonyl chloride, often a mixture of both mesylate and benzyl chloride is obtained. This mixture can be used directly – as described previously.

10


Some compounds of formula (V) can be prepared by reacting a compound of formula (Va) with a solution of HBr in an alcoholic solvent such as ethanol at low temperatures, preferably 0 °C in a polar organic solvent, such as ethanol or methanol;



15 (Va)

in which V, W, R<sup>3</sup> and R<sup>15</sup> are as defined for compounds of formula (II).

Certain compounds of formula (II) can also be prepared as outlined in Scheme 5:




Scheme 5

in which R<sup>3</sup>, V, W and R<sup>15</sup> are as outlined for compounds of formula (II) or  
 5 protected derivatives thereof. The aryl iodide (VII) can undergo a Stille coupling reaction  
 with vinyltributyltin in the presence of a suitable palladium catalyst at elevated  
 temperatures, preferably 85 – 100 °C. The alkene is converted to the aldehyde by reaction  
 with osmium tetroxide in suitable solvents such as tertiary butanol, THF and water. The  
 aldehyde can then be reacted with compounds of formula (VIII), under reductive amination  
 10 conditions. Preferably reacting in the presence of sodiumtriacetoxy borohydride in a  
 suitable organic solvent, such as THF or DCM.


Compounds of formula (VIII) can be prepared from compounds of formula (VI), by  
 reacting the phenolic compound of formula (V) with L<sup>2</sup>C(R<sup>1</sup>, R<sup>2</sup>)CO<sub>2</sub>R<sup>15</sup> in the presence of  
 a base such as potassium carbonate in a suitable solvent such as DMF.

15 Compounds of formula (VIII) can be prepared from compounds of formula (VI) by  
 reacting with a compound of formula (IV) as described previously in Scheme 1.:.



The amino group of compounds of formula (VI) may need to be protected prior to reaction with compounds of formula (IV). Suitable protecting groups are BOC, trityl or benzyl, which can be removed readily using the procedures described previously. Some protected compounds of formula (VI) are commercially available.

5 Compounds of formula (IX) can be prepared from compounds of formula (I) by coupling with a compound of formula (X) as shown in Scheme 6:



Scheme 6

in which R<sup>1</sup>, R<sup>3</sup>, R<sup>6</sup>, V, W, X, Y, Z and HET are as defined in compounds of  
 10 formula (I) or protected derivatives thereof. The coupling can be carried out using standard coupling methods. For example, compounds of formula (I) can be converted to the acid chloride using a reagent such as oxalyl chloride and subsequently reacted with an acyl sulfonamide of formula (X) using a suitable base such as hunigs base in a suitable solvent such as DCM. Alternatively compounds of formula (I) can be directly coupled with  
 15 acyl sulfonamides of formula (X) using a suitable coupling agent such as PyBOP or HATU or CDI with a suitable base such as Hunigs base or DBU in a suitable solvent such as DCM or THF. In a further aspect, the present invention provides the use of a compound of formula (I), a prodrug, pharmaceutically acceptable salt or solvate thereof for use in therapy.

20 The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of CRTh2 receptor activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of PGD<sub>2</sub> and its metabolites. Examples of such conditions/diseases include:

25 1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin

and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases;

5 hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of

10 chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polypsis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

15 2. bone and joints: arthritides associated with or including osteoarthritis/osteoarthritis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy;

20 septic arthritis and other infection-related arthropathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma;

25 systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's

30 arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and

Familial Hibernian Fever, Kikuchi disease; drug-induced arthalgias, tendonititides, and myopathies;

3. pain and connective tissue remodelling of musculoskeletal disorders due to injury [for example sports injury] or disease: arthritides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritis, scleroderma, mixed connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis);
- 10 4. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;
- 15 5. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmritis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;
- 20 6. gastrointestinal tract: glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, and food-related allergies which may have effects remote from the gut (for example migraine, rhinitis or eczema);
- 25 7. abdominal: hepatitis, including autoimmune, alcoholic and viral; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic;
- 30 8. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer;

acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);

9. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or

5 chronic graft versus host disease;

10. CNS: Alzheimer's disease and other dementing disorders including CJD and nvCJD; amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; acute and chronic pain (acute, intermittent or persistent, whether of central or peripheral origin) including visceral

15 pain, headache, migraine, trigeminal neuralgia, atypical facial pain, joint and bone pain, pain arising from cancer and tumor invasion, neuropathic pain syndromes including diabetic, post-herpetic, and HIV-associated neuropathies; neurosarcoidosis; central and peripheral nervous system complications of malignant, infectious or autoimmune processes;

16 11. other auto-immune and allergic disorders including Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome;

12. other disorders with an inflammatory or immunological component; including acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and

20 paraneoplastic syndromes;

13. cardiovascular: atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis , inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and 25 peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins;

14. oncology: treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as

30 Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,

15. gastrointestinal tract: Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, microscopic colitis, indeterminant colitis, irritable bowel disorder, irritable bowel syndrome, non-inflammatory diarrhea, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and  
5 eczema.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat diseases in which the  
10 chemokine receptor belongs to the CRTh2 receptor subfamily.

Particular conditions which can be treated with the compounds of the invention are asthma, rhinitis and other diseases in which raised levels of PGD<sub>2</sub> or its metabolites. It is preferred that the compounds of the invention are used to treat asthma.

In a further aspect, the present invention provides the use of a compound of  
15 formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In a further aspect, the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy in combination with drugs  
20 used to treat asthma and rhinitis (such as inhaled and oral steroids, inhaled β<sub>2</sub>-receptor agonists and oral leukotriene receptor antagonists).

The invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or  
25 sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis the compounds of the invention may be combined with agents such as tumour necrosis factor alpha (TNF-  
30 α) inhibitors such as anti-TNF monoclonal antibodies (for example Remicade, CDP-870 and adalimumab) and TNF receptor immunoglobulin molecules (such as Enbrel); non-selective cyclo-oxygenase (COX)-1 / COX-2 inhibitors whether applied topically or

systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin), COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); glucocorticosteroids (whether administered by topical, oral, intramuscular, intravenous, or intra-articular routes); methotrexate, lefunomide; hydroxychloroquine, d-penicillamine, auranofin or other parenteral or oral gold preparations.

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepronalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2-cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonist for leukotrienes( LT)B4, LTC4, LTD4, and LTE4. selected from the group consisting of the phenothiazin-3-1s such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, irlukast (CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the invention together with a phosphodiesterase (PDE) inhibitor such as the methylxanthanines including theophylline and aminophylline; and selective PDE isoenzyme inhibitors including PDE4 inhibitors and inhibitors of the isoform PDE4D, and inhibitors of PDE5.

The present invention still further relates to the combination of a compound of the invention together with histamine type 1 receptor antagonists such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, and mizolastine applied orally, topically or parenterally.

The present invention still further relates to the combination of a compound of the invention together with a gastroprotective histamine type 2 receptor antagonist.

The present invention still further relates to the combination of a compound of the invention with antagonists of the histamine type 4 receptor.

- 5 The present invention still further relates to the combination of a compound of the invention together with an alpha-1/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride,  
10 and ethynorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents including muscarinic receptor (M1, M2, and M3) antagonists such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide;

- 15 tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

The present invention still further relates to the combination of a compound of the invention together with a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol .

- 20 The present invention still further relates to the combination of a compound of the invention together with a chromone, including sodium cromoglycate and nedocromil sodium.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

- 25 The present invention still further relates to the combination of a compound of the invention together with an inhaled glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide, and mometasone furoate.

- 30 The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1

(MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP-12.

The present invention still further relates to the combination of a compound of the invention together with modulators of chemokine receptor function such as antagonists of CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family.

The present invention still further relates to the combination of a compound of the invention together with a cytokine or modulator of cytokine function, including alpha-, beta-, and gamma-interferon; interleukins (IL) including IL1 to 15, and interleukin antagonists or inhibitors, including agents which act on cytokine signalling pathways.

The present invention still further relates to the combination of a compound of the invention together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (omalizumab).

15 The present invention still further relates to the combination of a compound of the invention together with other systemic or topically-applied anti-inflammatory agents including thalidomide and derivatives, retinoids, dithranol, and calcipotriol.

The present invention still further relates to the combination of a compound of the invention together with an antibacterial agent including penicillin derivatives,

20 tetracyclines, macrolides, beta-lactams, flouroquinolones, and inhaled aminoglycosides; and antiviral agents including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir; amantadine, rimantadine; ribavirin; zanamavir and oseltamavir; protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir; nucleoside reverse transcriptase inhibitors such as didanosine, lamivudine, stavudine, zalcitabine, zidovudine; non-nucleoside reverse 25 transcriptase inhibitors such as nevirapine, efavirenz.

The present invention still further relates to the combination of a compound of the invention together with cardiovascular agents such as calcium channel blockers, beta-adrenoceptor blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-2 receptor antagonists; lipid lowering agents such as statins, and fibrates; modulators of 30 blood cell morphology such as pentoxyfylline; thrombolytics, and anticoagulants including platelet aggregation inhibitors.

The present invention still further relates to the combination of a compound of the invention together with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegiline and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine 5 reuptake inhibitors, NMDA antagonists, nicotine agonists, dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metrifonate.

The present invention still further relates to the combination of a compound of the invention together with agents for the treatment of acute and chronic pain, including 10 centrally and peripherally-acting analgesics such as opioid analogues and derivatives, carbamazepine, phenytoin, sodium valproate, amitryptiline and other antidepressant agents, and non-steroidal anti-inflammatory agents.

The present invention still further relates to the combination of a compound of the invention together with parenterally or topically-applied local anaesthetic agents such as 15 lignocaine.

The present invention still further relates to the combination of a compound of the invention together with (i) tryptase inhibitors; (ii) platelet activating factor (PAF) antagonists; (iii) interleukin converting enzyme (ICE) inhibitors; (iv) IMPDH inhibitors; (v) adhesion molecule inhibitors including VLA-4 antagonists; (vi) cathepsins; (vii) MAP 20 kinase inhibitors; (viii) glucose-6 phosphate dehydrogenase inhibitors; (ix) kinin-B.<sub>sub1</sub>. - and B.<sub>sub2</sub>. -receptor antagonists; (x) anti-gout agents, e.g., colchicine; (xi) xanthine oxidase inhibitors, e.g., allopurinol; (xii) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (xiii) growth hormone secretagogues; (xiv) transforming growth factor (TGF $\beta$ ); (xv) platelet-derived growth factor (PDGF); (xvi) 25 fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) Tachykinin NK.<sub>sub1</sub>. and NK.<sub>sub3</sub>. receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892; (xxi) TNF $\square$  converting 30 enzyme inhibitors (TACE); (xxii) induced nitric oxide synthase inhibitors (iNOS) or (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists) (xxiv) inhibitors of P38

The compounds of the present invention may also be used in combination with anti-osteoporosis agents including hormonal agents such as raloxifene, and biphosphonates such as alendronate.

The compounds of the invention may also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAIDs) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, analgesics, and intra-articular therapies such as corticosteroids and hyaluronic acid derivatives, and nutritional supplements such as glucosamine.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel; antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecins);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 $\alpha$ -reductase such as finasteride;

- (iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab and the anti-erbB1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
- (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin  $\alpha v \beta 3$  function and angiostatin);
- (vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO00/40529, WO 00/41669, WO01/92224, WO02/04434 and WO02/08213;
- (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
- (viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
- (ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor,

approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

In a still further aspect, the present invention provides the use of a compound of formula 5 (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of CRTh2 receptor activity is beneficial.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" 10 and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating diseases mediated by PGD2 or its metabolites wherein the prostanoid binds to its receptor (especially CRTh2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug 15 thereof, as hereinbefore defined.

The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

20 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and 25 the disorder indicated.

The compound of formula (I), prodrugs and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

30 Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w,

still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as herein 5 before defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the 10 form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.

The invention will now be illustrated by the following non-limiting examples in 15 which, unless stated otherwise:


- (i) when given,  $^1\text{H}$  NMR data is quoted in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard;
- (ii) mass spectra (MS): generally only ions which indicate the parent mass are reported, 20 and unless otherwise stated the mass ion quoted is the positive mass ion -  $(\text{M}+\text{H})^+$ ;
- (iii) the title compounds of the examples and methods were named using the ACD/name and ACD/name batch (version 6.0) from Advanced Chemical Development Inc, Canada;
- (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Ex-Terra reverse phase silica column;
- 25 (v) solvents were dried with  $\text{MgSO}_4$  or  $\text{Na}_2\text{SO}_4$
- (vi) the following abbreviations are used:

aq	aqueous
DCM	dichloromethane
DMF	<i>N,N</i> -dimethylformamide
30 ether	diethyl ether
EtOAc	ethyl acetate
EtOH	ethanol

h	hour
HATU	<i>O</i> -(7-Azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphonate
HCl	hydrochloric acid
5 SCX	sulphonic acid resin
NaOH	sodium hydroxide
K <sub>2</sub> CO <sub>3</sub>	potassium carbonate
KOH	potassium hydroxide
MeOH	methanol
10 NaHCO <sub>3</sub>	sodium hydrogen carbonate
NMP	<i>N</i> -methylpyrrolidine
Pd(dppf)Cl <sub>2</sub>	[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane
Pd <sub>2</sub> dba <sub>3</sub>	<i>bis</i> (dibenzylideneacetone)palladium (0)
15 RPHPLC	reverse phase high performance liquid chromatography
RT	room temperature
TFA	trifluoroacetic acid
THF	tetrahydrofuran

## Example 1

Sodium 3-(2-{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl) propanoate



(i) 4-chloro-2-formylphenyl trifluoromethanesulfonate

5 Phenyl triflimide ( $\text{Tf}_2\text{NPh}$ ) (3.05 g) was added portionwise to a solution of 5-chloro-2-hydroxybenzaldehyde (1.13 g) and triethylamine (1.2 ml) in DMF (5 ml) and stirred for 4 h. The reaction was quenched with water and then extracted with ether. The ether layer was washed with water, brine, then dried ( $\text{MgSO}_4$ ) and evaporated under reduced pressure. The residue was purified by chromatography on silica (eluent 4:1 then 2:1 petrol/ DCM) to give the sub-title compound, yield 1.89 g

<sup>1</sup>H NMR  $\text{CDCl}_3$ :  $\delta$  10.23 (1H, s), 7.97 (1H, d), 7.67 (1H, dd), 7.36 (1H, d).

(ii) methyl (2E)-3-(4-chloro-2-formylphenyl)acrylate

A mixture of methyl acrylate (1 ml), the product of step (i) (1.36 g), triethylamine (1.3 ml) and  $\text{Pd}(\text{dpff})\text{Cl}_2$  (35 mg) in THF (4 ml) was heated at reflux for 8 h. Water was added and extracted with ether. The ether layer was washed with water, brine, then dried ( $\text{MgSO}_4$ ) and evaporated under reduced pressure. The residue was purified by chromatography on silica (eluent 2:1 petrol/ ether) to give the sub-title compound, yield 410 mg

<sup>1</sup>H NMR  $\text{CDCl}_3$ :  $\delta$  10.27 (1H, s), 8.44 (1H, d), 7.86 (1H, s), 7.59 (2H, d), 6.38 (1H, d), 3.84 (3H, s).

(iii) methyl 3-[4-chloro-2-(hydroxymethyl)phenyl]propanoate

A mixture of the product of step (ii) (390 mg), 5 % Platinum on carbon (151 mg) in EtOAc (10 ml) was stirred under 4 ATM of hydrogen for 2 days. The reaction was filtered and the filtrate was evaporated under reduced pressure to give the sub-title compound as a yellow oil (376 mg).

<sup>1</sup>H NMR  $\text{CDCl}_3$ :  $\delta$  7.39 (1H, d), 7.22 (1H, dd), 7.12 (1H, d), 4.70 (2H, s), 4.63 (3H, s), 2.97 (2H, t), 2.66 (2H, t).

## (iv) methyl 3-[4-chloro-2-(chloromethyl)phenyl]propanoate

Methane sulfonyl chloride (0.18 ml) was added to a solution of the product of step (iii) (437 mg) and triethylamine (0.4 ml) in DCM (4 ml) and stirred for 3h. Water was added and the mixture was extracted with DCM. The organic phase was dried ( $\text{MgSO}_4$ ) and

5 evaporated under reduced pressure. The residue was purified by chromatography on silica (eluent 1:2 petrol/ ether) to give the sub-title compound, yield 273 mg.

$^1\text{H}$  NMR  $\text{CDCl}_3$ :  $\delta$  7.34 (1H, d), 7.24 (1H, dd), 7.16 (1H, d), 4.60 (2H, s), 3.69 (3H, s),  
3.03 (2H, t), 2.66 (2H, t).

## 10 (iva) (methyl 3-(4-chloro-2-[(methylsulfonyl)oxy]methyl)phenyl) propanoate

The mesylate was also obtained, yield 170 mg.

$^1\text{H}$  NMR  $\text{CDCl}_3$ :  $\delta$  7.39 (1H, d), 7.33 (1H, dd), 7.20 (1H, d), 5.28 (2H, d), 3.67 (3H, s),  
3.01 (3H, s), 3.0 (2H, t), 2.64 (2H, t).

15  $^1\text{H}$  NMR  $\text{CDCl}_3$ :  $\delta$  7.41-6.91 (8H, m), 4.21 (3H, s), 4.14 (2H, q), 3.66 (2H, s), 3.12 (4H, t),  
2.93 (2H, t), 2.58 (2H, t), 2.40 (4H, t), 1.26 (3H, t).

(v) *tert*-butyl 4-(benzylsulfonyl)piperazine-1-carboxylate

Triethylamine (6 ml) was added to a stirred solution of *tert*-butyl piperazine-1-carboxylate (7.75 g) and benzylsulfonyl chloride (7.92 g) in DCM, and then stirred overnight. The solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc, washed with water, dried ( $\text{MgSO}_4$ ) and evaporated under reduced pressure to give the sub-title compound as a white solid, yield 15.36 g

MS: ESI(-ve) 339(M-H)

25

## (vi) 1-(benzylsulfonyl)piperazine

TFA (10 ml) was added to a solution of the product of step (v) (15.36 g) in DCM (20 ml) and stirred overnight. The reaction mixture was concentrated under reduced pressure to give an oil, which was then triturated with diethyl ether to give a pink solid, yield 5.61 g.

30  $^1\text{H}$  NMR DMSO-D6:  $\delta$  8.74 (1H, s, br), 7.46-7.39 (5H, m), 4.55 (2H, s), 3.29 (4H, t), 3.09 (4H, t).

(vii) methyl 3-(2-{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl) propanoate

A mixture of the product of step (iv) (35 mg), the product of step (iva) (170 mg), the product of step (vi) (293 mg) and  $K_2CO_3$  (241 mg) in ethanol (4 ml) was stirred for 2.5 days. Aqueous ammonium chloride was added and the reaction was extracted with DCM,

5 dried ( $MgSO_4$ ) and evaporated under reduced pressure. The residue was purified by chromatography on silica (eluent 2:3 petrol/ ether) to give the sub-title compound was obtained as a mixture of methyl and ethyl esters, yield 206 mg.

(viii) Sodium 3-(2-{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl) propanoate

10 A solution of the product of step (vii) (204 mg), NaOH (0.44 ml), THF (2 ml), methanol (2 ml) was stirred for 3 h. The solvent was removed under reduced pressure, the residue was washed with ether and then recrystallised from MeCN/MeOH to give the title compound as a white solid, yield 185 mg.

$^1H$  NMR DMSO-D<sub>6</sub>: δ 7.42-7.14 (8H, m), 4.41 (2H, s), 3.49 (2H, s), 3.14 (4H, s), 2.78


15 (2H, t), 2.41 (4H, s), 2.08 (2H, t).

MS: ESI(+ve) 439(M+1)

### Example 2

3-(2-{{(3S)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl}methyl}-4-chlorophenyl) propanoic

20 acid



(i) *tert*-butyl (3*S*)-3-methylpiperazine-1-carboxylate

Triethylamine (2.85 ml) was added to a solution of (S)-2-methyl piperazine (1 g) in methanol (25 ml), this was followed by portionwise addition of BOC anhydride (2.18 g).

25 The reaction mixture was stirred for 17 h, then concentrated under reduced pressure.

Water was added to the residue and extracted EtOAc (x 3), dried ( $MgSO_4$ ) and evaporated under reduced pressure. The residue was purified by chromatography on silica (eluent EtOAc, then 9:1:1 EtOAc:MeOH:NH<sub>3</sub>) to give the sub-title compound as a colourless oil, yield 1.3 g.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 4.04-3.82 (2H, m), 2.95 (1H, d), 2.81-2.66 (3H, m), 2.48-2.32 (1H, m), 1.47 (9H, s), 1.05 (3H, d).

(ii) *tert*-butyl (3*S*)-4-(benzylsulfonyl)-3-methylpiperazine-1-carboxylate

5 A mixture of the product of step (i) (650 mg), K<sub>2</sub>CO<sub>3</sub> (1.15 g), DCM (6 ml) and water (6 ml) were stirred vigorously. Benzylsulfonyl chloride (992 mg) was added portionwise over 2 min and then stirred for 4.5 h. The reaction was diluted with DCM, washed with water, brine, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to give the sub-title compound as a white solid, yield 1.06 g.

10 <sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.38 (5H, s), 4.20 (2H, d), 4.04-3.82 (2H, m), 2.95 (1H, d), 2.81-2.66 (3H, m), 2.48-2.32 (1H, m), 1.47 (9H, s), 1.05 (3H, d).

(iii) (2*S*)-1-(benzylsulfonyl)-2-methylpiperazine, trifluoroacetic acid salt

he sub-title compound was prepared by the method of example 1 step (vi) using the  
15 product of step (ii) to give an off-white solid, yield 1.03 g.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.41 (5H, s), 4.24 (2H, d), 4.11-3.98 (1H, m), 3.4-3.26 (2H, m), 3.11 (1H, d), 2.97 (2H, s), 2.81-2.65 (1H, m), 1.32 (3H, d).

(iv) methyl 3-(4-chloro-2-{[(methylsulfonyl)oxy]methyl}phenyl)propanoate

20 Methanesulfonyl chloride (0.39 ml) was added to a solution of the product of example 1 step (iii) (946 mg) and triethyl amine (0.85 ml) in DCM (10 ml), and then stirred for 3 h. Water was added and the mixture was extracted with DCM (x 3). The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to give a 2.5:1 mixture of chloride and mesylate as for example 1 step (iv) and (iva). The mixture was  
25 used directly without purification.

(v) methyl 3-(2-{[(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl}-4-chlorophenyl)propanoate

The mixture of products from step (iv) (200 mg), the product of step (iii) (332 mg) and  
30 K<sub>2</sub>CO<sub>3</sub> (263 mg) in DMF (5 ml) were charged to a flask and stirred for 2.5 days. The reaction was diluted with water, extracted with EtOAc (x 3). The combined organic extracts were dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was

purified by chromatography on silica (eluent 3:2 then 2:3 iso-hexane:ether) to give the sub-title compound as a colourless oil, yield 211 mg.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.39 (5H, s), 7.28-7.14 (2H, m), 7.09 (1H, d), 4.19 (2H, d), 3.92-3.81 (1H, m), 3.67 (3H, m), 3.43-3.3 (2H, m), 3.27-3.18 (1H, m), 3.09 (1H, td), 2.97 (2H, t), 5 2.65-2.55 (3H, m), 2.52 (1H, d), 2.14 (1H, dd), 1.93 (1H, td), 1.24 (3H, d).

(vi) 3-(2-[(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl)-4-chlorophenylpropanoic acid

The title compound was prepared by the method of example 1 step (viii). The product was 10 isolated by reverse phase HPLC.


<sup>1</sup>H NMR DMSO-D6: δ 7.45-7.33 (5H, m), 7.3 (1H, s), 7.23 (2H, s), 4.46-4.33 (2H, m), 3.84-3.71 (1H, m), 3.48-3.25 (3H, m), 3.06 (1H, t), 2.86 (2H, t), 2.63-2.39 (4H, m), 2.21 (1H, dd), 1.99-1.86 (1H, m), 1.17 (3H, d).

MS: APCI(+ve) 451(M+H)

15

### Example 3

Sodium 3-(4-chloro-2-[(3*S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl)propanoate



20 (i) *tert*-butyl (3*S*)-3-methyl-4-(phenylsulfonyl)piperazine-1-carboxylate

The product of example 2 step (i) (0.65 g) was dissolved in DCM and triethylamine (1.36 ml) was added, followed by dropwise addition of benzenesulfonyl chloride (0.5 ml), and then stirred for 24 h. Further benzene sulfonyl chloride (0.15 ml) was added and stirred for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was

25 purified by chromatography on silica (eluent 8:2 iso-hexane: EtOAc) to give the sub-title compound as a pale yellow solid, yield 1 g.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.81 (2H, dt), 7.62-7.47 (3H, m), 4.17-4.07 (2H, m), 3.86-3.71 (1H, m), 3.62 (1H, d), 3.12 (1H, dt), 3.04-2.88 (1H, m), 2.87-2.7 (1H, m), 1.42 (9H, s), 1.01 (3H, d).

(ii) (2*S*)-2-methyl-1-(phenylsulfonyl)piperazine

The sub-title compound was prepared by the method of example 1 step (vi) using the product of step (i).

5   <sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.81 (2H, d), 7.64 (1H, t), 7.56 (2H, t), 4.41-4.28 (1H, m), 3.86 (1H, d), 3.58-3.4 (1H, m), 3.33 (1H, d), 3.14 (2H, s), 3.06-2.9 (1H, m), 1.23 (3H, d).

(iii) methyl 3-(4-chloro-2-[(3*S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl}phenyl)propanoate

10 The sub-title compound was prepared by the method of example 2 step (v) using the product of example 2 step (iv) and the product of step (ii).

1H NMR CDCl<sub>3</sub>: δ 7.82 (2H, d), 7.62-7.45 (3H, m), 7.23-7.05 (3H, m), 4.17-4.05 (1H, m), 3.65 (3H, s), 3.62-3.58 (1H, m), 3.44-3.28 (2H, m), 3.19 (1H, td), 2.96 (2H, t), 2.68 (1H, d), 2.63-2.48 (3H, m), 2.21 (1H, dd), 2.03 (1H, td), 1.12 (3H, d).

15

(iv) Sodium 3-(4-chloro-2-[(3*S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl}phenyl)propanoate

The title compound was prepared by the method of example 1 step (viii). The product was isolated by reverse phase HPLC.

20   <sup>1</sup>H NMR DMSO-D6: δ 7.8 (2H, d), 7.68 (1H, t), 7.61 (2H, t), 7.24 (1H, s), 7.18 (2H, s), 4.03-3.94 (1H, m), 3.57 (1H, d), 3.35 (2H, s), 3.11 (2H, t), 2.75 (2H, t), 2.64 (1H, d), 2.15 (2H, t), 2.0 (1H, dd), 1.89 (1H, td), 1.03 (3H, d).


MS: APCI(+ve) 437 (M+H)

25

30

## Example 4

3-(4-chloro-2-[(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl]methyl)phenyl propanoic acid



5 (i) *tert*-butyl (3*S*)-3-methyl-4-(phenylacetyl)piperazine-1-carboxylate

The sub-title compound was prepared by the method of example 2 step (ii) using the product of example 2 step (i), phenylacetyl chloride and NaHCO<sub>3</sub> as base instead of K<sub>2</sub>CO<sub>3</sub>.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.32 (2H, t), 7.28-7.18 (3H, m), 4.87-4.76 (1H, m), 4.49-4.38 (1H, m),  
10 4.18-3.92 (1H, m), 3.87-3.68 (2H, m), 3.01-2.81 (2H, m), 2.8-2.68 (1H, m), 2.62-2.5 (1H, m), 1.45 (9H, s), 1.18-1.05 (3H, m).

(ii) (2*S*)-2-methyl-1-(phenylacetyl)piperazine

The sub-title compound was prepared by the method of example 1 step (vi) using the product of step (i).

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.32 (2H, t), 7.27-7.15 (3H, m), 4.84-4.64 (1H, m), 4.55-4.32 (1H, m), 4.06-3.87 (1H, m), 3.75 (2H, s), 3.27-3.13 (2H, m), 3.05 (1H, dd), 2.83 (1H, td), 1.15 (3H, d).

20 (iii) methyl 3-(4-chloro-2-[(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl]methyl)phenylpropanoate

The sub-title compound was prepared by the method of example 1 step (vi) using the product of step (i).

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.32 (2H, t), 7.27-7.18 (4H, m), 7.17 (1H, d), 7.1 (1H, d), 4.83-4.74 (1H, m), 4.44 (1H, d), 4.06-3.98 (1H, m), 3.71 (2H, s), 3.66 (3H, s), 3.57-3.5 (1H, m),  
25 3.42-3.16 (2H, m), 2.98 (2H, t), 2.95-2.86 (1H, m), 2.81-2.73 (1H, m), 2.68-2.53 (3H, m), 2.2-2.13 (1H, m), 2.05-1.92 (1H, m), 1.85-1.76 (1H, m).

MS: ESI(+ve) 429 (M+H)

(iv) 3-(4-chloro-2-[(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl]methyl)phenyl propanoic acid


The title compound was prepared by the method of example 1 step (viii) using the product of step (iii).

5  $^1\text{H}$  NMR  $\text{CDCl}_3$ :  $\delta$  7.32-7.28 (3H, m), 7.25-7.16 (5H, m), 4.59-4.50 (1H, m), 4.23-4.15 (1H, m), 3.77-3.62 (2H, m), 3.41 (2H, q), 3.11 (1H, t), 2.88 (2H, t), 2.8-2.55 (2H, m), 2.48 (2H, t), 2.05 (1H, dd), 1.85 (1H, dd), 1.13-1.05 (3H, m).

MS: ESI(+ve) 415 (M+H)

10 Example 5

3-[4-chloro-2-((3*S*)-3-methyl-4-[(4-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoic acid



(i) (3*S*)-3-methyl-1-(triphenylmethyl)-piperazine

15 (*S*)+-2-methylpiperazine (10 g) was dissolved in acetonitrile (140 ml) and cooled to 5-10 °C whereupon triethylamine (35 ml) was added, followed by drop wise addition of a solution of trityl chloride (27.9 g) in DCM (80 ml). The reaction was stirred for 1 h at RT. The resulting slurry was cooled to approximately 0 °C then filtered. The filtrate was evaporated *in vacuo* and the residue was purified by chromatography (silica, 0-1 % MeOH/20 DCM as eluent), then triturated with ether to give the sub-title compound as a white solid yield, 29.8 g.

$^1\text{H}$  NMR  $\text{CDCl}_3$ :  $\delta$  7.49-7.37 (6H, m), 7.26 (6H, t), 7.15 (3H, t), 3.38-3.28 (1H, m), 3.22 (1H, dd), 3.11-2.99 (3H, m), 1.74-1.6 (1H, m), 1.44-1.3 (1H, m), 1.11 (3H, d).

25 (ii) (2*S*)-1-piperazinecarboxylic acid, 2-methyl-4-(triphenylmethyl)-1,1-dimethylethyl ester Triethylamine (24.3 ml) was added to a solution of the product from part a) (29.8 g) in methanol (350 ml). BOC-anhydride (19 g) was then added to the reaction mixture and stirred overnight. The solvents were evaporated under reduced pressure. The residue was

partitioned between EtOAc and saturated brine. The organic layer was separated and washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) the concentrated *in vacuo* to give the sub-title compound as a foam, yield, 35 g.

<sup>1</sup>H NMR ( $\text{CDCl}_3$ )  $\delta$  7.49-7.16 (15H, m), 4.13 (1H, t), 3.74 (1H, d), 3.33 (1H, t), 2.97 (4H, s) m), 1.68 (3H, dd) and 1.33 (9H, s).

(iii) (2*S*)-2-methyl-1-piperazinecarboxylic acid-1,1-dimethylethyl ester  
2M HCl (50 ml) was added drop wise to a solution of the product of part b) (34 g) in ethanol (1500 ml), the reaction was stirred for 1.5 h. Solid  $\text{NaHCO}_3$  (8.4 g) was added and 10 stirred for 1 h, then concentrated under reduced pressure. The residue was purified by chromatography (silica, 5-10 % MeOH/ DCM as eluent) to remove the by-products, then eluted with 10 % MeOH/DCM to give the sub-title compound, yield 16.5 g.  
<sup>1</sup>H NMR ( $\text{CDCl}_3$ )  $\delta$  4.51 (1H, t), 4.07 (1H, d), 3.46-3.33 (2H, m), 3.21 (1H, d), 3.09 (1H, dd), 2.88 (1H, td) and 1.49-1.43 (12H, m).

15

(iv) *tert*-butyl (2*S*)-4-[5-chloro-2-(3-methoxy-3-oxopropyl)benzyl]-2-methylpiperazine-1-carboxylate

The sub-title compound was prepared by the method of example 2 step (v) using the product of example 2 step (iv) and the product of step (iii).

20

<sup>1</sup>H NMR ( $\text{CDCl}_3$ )  $\delta$  7.28-7.26 (1H, m), 7.19 (1H, dd), 7.11 (1H, d), 4.25-4.16 (1H, m), 3.80 (1H, d), 3.67 (3H, s), 3.4 (2H, q), 3.09-2.95 (3H, m), 2.7 (1H, d), 2.67-2.57 (3H, m), 2.2 (1H, dd), 1.9 (1H, td), 1.46 (9H, s), 1.20 (3H, d).

25

(v) methyl 3-(4-chloro-2-[(3*S*)-3-methylpiperazin-1-yl]methyl)phenyl propanoate, TFA salt

The sub-title compound was prepared by the method of example 1 step (vi) using the product of step (iv).

<sup>1</sup>H NMR ( $\text{CDCl}_3$ )  $\delta$  7.44-7.4 (2H, m), 7.24 (1H, s), 4.5 (1H, d), 4.45 (1H, d), 4.01-3.91 (1H, m), 3.76-3.52 (6H, m), 3.62 (3H, s), 2.95 (2H, t), 2.78 (2H, t), 1.48 (13H, d).

30

(vi) methyl 3-[4-chloro-2-((3*S*)-3-methyl-4-[(4-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoate

The product of step (v) (360 mg) was dissolved in DCM (5 ml), this was followed by addition of a solution of NaHCO<sub>3</sub> (218 mg) in water (5 ml). (4-methylphenyl)methane sulfonyl chloride (280 mg) was added portionwise and stirred for 1 day, then additional NaHCO<sub>3</sub> and sulfonyl chloride were added and stirred for 3 days overall. The reaction was 5 diluted with water and extracted with DCM (x 3). The combined organic layers were washed (brine), dried (MgSO<sub>4</sub>) then concentrated under reduced pressure to give the subtitle compound as a pale yellow oil, yield 210 mg.

MS: ESI(+ve) 479 (M+H)

10 (vii) 3-[4-chloro-2-((3*S*)-3-methyl-4-[(4-methylbenzyl)sulfonyl]piperazin-1-yl}methyl)phenyl]propanoic acid

The title compound was prepared by the method of example 1 step (viii) using the product of step (vi).


<sup>1</sup>H NMR CD<sub>3</sub>OD: δ 7.31 (2H, d), 7.25 (1H, s), 7.22-7.15 (4H, m), 4.26 (2H, s), 3.77-3.62

15 (2H, m), 3.41 (2H, q), 3.11 (1H, t), 2.88 (2H, t), 2.8-2.55 (2H, m), 2.48 (2H, t), 2.34 (3H, s), 2.05 (1H, dd), 1.85 (1H, dd), 1.13-1.05 (3H, m).

MS: ESI(+ve) 415 (M+H)

#### Example 6

20 3-[4-chloro-2-((3*S*)-3-methyl-4-[(3-methylbenzyl)sulfonyl]piperazin-1-yl}methyl)phenyl]propanoic acid



(i) methyl 3-[4-chloro-2-((3*S*)-3-methyl-4-[(3-methylbenzyl)sulfonyl]piperazin-1-yl}methyl)phenyl]propanoate

The product of example 5 step (v) (400 mg) was dissolved in DCM (5 ml), this was followed by addition of a solution of K<sub>2</sub>CO<sub>3</sub> (520 mg) in water (4 ml). (3-methylphenyl)methane sulfonyl chloride (307 mg) was added portionwise and stirred for 2h. The reaction was diluted with water and extracted with DCM (x 3). The combined 5 organic layers were washed (brine), dried (MgSO<sub>4</sub>) then concentrated under reduced pressure to give the sub-title compound, yield 190 mg.

MS: ESI(+ve) 479 (M+H)

(ii) 3-[4-chloro-2-((3S)-3-methyl-4-[(3-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoic acid


The title compound was prepared by the method of example 1 step (viii) using the product of step (i).

<sup>1</sup>H NMR CD<sub>3</sub>OD: δ 7.40 (1H, t), 7.42-7.38 (2H, m), 7.3-7.2 (4H, m), 4.44-4.34 (3H, m), 4.19-4.09 (2H, m), 3.56 (1H, d), 3.43-3.27 (2H, m), 3.15 (1H, d), 3.03-2.89 (3H, m), 2.83 (2H, t), 2.78-2.75 (1H, m), 2.36 (3H, s), 1.3 (3H, d).

MS: ESI(+ve) 465 (M+H)

### Example 7

3-[4-chloro-2-((3S)-3-methyl-4-[(2-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoic acid



(i) methyl 3-[4-chloro-2-((3S)-3-methyl-4-[(2-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoate

25 The sub-title compound was prepared by the method of example 5 step (vi) using the product of example 5 step (v) and (2-methylphenyl)methane sulfonyl chloride.

MS: ESI(+ve) 479 (M+H)

(ii) 3-[4-chloro-2-((3S)-3-methyl-4-[(2-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoic acid


The title compound was prepared by the method of example 1 step (viii) using the product of step (i).

5  $^1\text{H}$  NMR CD<sub>3</sub>OD:  $\delta$  7.46 (1H, d), 7.44-7.34 (3H, m), 7.3-7.19 (3H, m), 4.45 (2H, s), 4.37 (1H, d), 4.21-4.09 (2H, m), 3.62 (1H, d), 3.45 (1H, td), 3.36-3.29 (1H, m), 3.18 (1H, d), 3.09 (1H, dd), 3.04-2.89 (3H, m), 2.83 (2H, t), 2.44 (3H, s), 1.34 (3H, d).

MS: APCI(+ve) 465 (M+H)

10 Example 8

(2-[(3S)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl)acetic acid



(i) Ethyl [2-(bromomethyl)phenyl]acetate

Acetyl bromide (1 ml) was added dropwise to ethanol (10 ml) at 0 °C and stirred for 5 min.

15 3-isochromanone (0.56 g) was added and then allowed to reach RT and stirred for 16 h.

The solvents were evaporated under reduced pressure to give the sub-title compound, yield 257 mg.

$^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  7.40 - 7.20 (4H, m), 4.60 (2H, s), 4.16 (2H, q), 3.79 (2H, s), 1.26 (3H, t).

20

(ii) (2-[(3S)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl)acetic acid


Ethyl [2-(bromomethyl)phenyl]acetate (257 mg), the product of example 2 step (ii) (266 mg), ethanol (2 ml) and triethylamine (0.28 ml) were charged to a flask and heated at 60 °C for 4 h, then cooled to RT and the solvents were evaporated under reduced pressure.

25 The reaction mixture was partitioned between EtOAc and water. The organic phase was dried (MgSO<sub>4</sub>) then concentrated under reduced pressure. The residue was purified by SCX resin to give the ester. The ester was dissolved in a mixture of THF (2 ml) and 25 % NaOH (1 ml), then stirred for 1 h at 57 °C. The reaction mixture was cooled to RT, then

acidified with acetic acid (10 ml) and then concentrated under reduced pressure. The residue was purified by RPHPLC to give the title compound as a white foam, yield 59 mg.  
<sup>1</sup>H NMR DMSO-D6: δ 7.79 (2H, m), 7.71-7.58 (3H, m), 7.24-7.13 (4H, m), 3.98 (1H, s),  
3.72 (1H, d), 3.65 (1H, d), 3.52 (1H, d), 3.41 (1H, d), 3.33 (1H, m), 3.27 (1H, d), 3.05 (1H,  
5 dt), 2.56 (1H, m), 2.0 (1H, dd), 1.8 (1H, td), 1.0 (3H, d).  
MS: APCI(-ve) 387 (M-H)

#### Example 9

(4-chloro-2-{[(3S)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl}phenyl)acetic acid



10

(i) 4-chloro-1-(chloromethyl)-2-iodobenzene

Borane (24 ml, 1 M solution in THF) was added to a solution of 4-chloro-2-iodobenzoic acid (2.4 g) in THF (15 ml) and heated at 50 °C for 1 h, then cooled to RT. The reaction mixture was quenched with methanol and then concentrated under reduced pressure (2 x 15 azeotrope with methanol) to give a white solid. The solid was dissolved in DCM (20 ml) and DMF (1 ml) was added followed by dropwise addition of thionyl chloride (0.93 ml), then stirred for 1 h. The solvents were evaoorated under reduced pressure and the residue was partitioned between diethyl ether and aqueous NaHCO<sub>3</sub>. The organic phase was separated, dried (MgSO<sub>4</sub>) then concentrated under reduced pressure to give the sub-title 20 compound, yield 2.4 g. Used directly without characterisation.

(ii) (4-chloro-2-iodophenyl)acetic acid

The product from step (i) (2.4 g) was dissolved in DMF (8 ml). Sodium cyanide (0.81 g) was added and the reaction mixture was stirred for 3 h at RT. Ice was added and a solid 25 formed, which was filtered. The solid was dissolved in aqueous KOH (2.65 g in 14 ml water) and heated at 100 °C for 24 h, then allowed to cool to RT. The reaetion mixture was washed with ether, then acidified and extracted with EtOAc (x 2). The combined organic extractes were dried (Na<sub>2</sub>SO<sub>4</sub>) then concentrated under redueed pressure to give the sub-title compound as a yellow solid 1.93 g.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.85 (1H, d), 7.32 (1H, dd), 7.22 (1H, d), 3.83 (2H, s).

(iii) methyl (4-chloro-2-iodophenyl)acetate

Trimethylsilyl chloride (2 ml) was added to a solution of the product from step (ii) (1.93 g) in MeOH (50 ml) and then stirred for 48 h. The solvent was evaportaed under reduced pressure and the residue was purified by chromatography on silica (eluent diethyl ether) to give the sub-title compound as a yellow oil, yield 1.93 g

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.84 (1H, d), 7.31 (1H, dd), 7.21 (1H, d), 3.78 (2H, s), 3.72 (3H, s).

10 (iv) methyl (4-chloro-2-vinylphenyl)acetate

The product from step (iii) (1.94 g), vinyltributyltin (2.19 ml), tetrakis palladium triphenylphosphine (0) (0.36 g) and toluene (10 ml) were charged to a flask and heated at 85 °C for 1 h, then at 110 °C for 16 h. The reaction mixture was allowed to cool to RT and the solvents evaporated under reduced pressure. The residue was purified by chromatography on silica (eluent 0-5 % diethyl ether:hexane) to give the sub-title compound as a yellow oil, yield 1.05 g

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.48 (1H, d), 7.21 (1H, dd), 7.14 (1H, d), 6.86 (1H, dd), 5.66 (1H, dd), 5.39 (1H, dd), 3.68 (3H, s), 3.66 (2H, s).

20 (v) methyl (4-chloro-2-formylphenyl)acetate

N-methyl-morpholine N-oxide (0.7 g) and osmium tetroxide (3 ml, 50 % solution in water) were added to a mixture of the product from step (iv) (1.05 g) in tertiary butanol (29 ml), THF (9.7 ml) and water (2.9 ml). The reaction was stirred for 1 h then poured into saturated aq. NaHCO<sub>3</sub> (50 ml) and extracted with ether (x 3). The combined organic extracts were dried (MgSO<sub>4</sub>) then concentrated under reduced pressure to give the sub-title compound as a yellow oil, yield 0.71 g.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 10.07 (1H, s), 7.82 (1H, d), 7.53 (1H, dd), 7.26 (1H, d), 4.02 (2H, s), 3.71 (3H, s).

(vi) methyl (4-chloro-2-[(*(3S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl)acetate

The product of step (v) (200 mg), the product of example 3 step (ii) (330 mg), MgSO<sub>4</sub> (0.54 g) and anhydrous THF (3 ml) were charged to a flask and stirred for 6 h. Sodium triacetoxy borohydride (0.57 g) was added portionwise and the mixture was stirred for 16 h, then partitioned between 2 M Na<sub>2</sub>CO<sub>3</sub> and EtOAc. The organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. The residue was purified by SCX (eluent with MeCN, MeOH then 7 % NH<sub>3</sub> in MeOH). The product containing fractions were combined and then purified by chromatography on silica (1:1 diethyl ether:hexane) to give the sub-title compound as a colourless oil, yield 114 mg.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.81 (2H, d), 7.54 (3H, m), 7.21 (2H, m), 7.13 (1H, d), 4.07 (1H, m), 3.79 (1H, d), 3.32 (1H, d), 3.32 (1H, d), 3.17 (1H, td), 2.63 (1H, d), 2.49 (1H, d), 2.18 (1H, dd), 2.0 (1H, td), 1.11 (3H, d).


(vii) (4-chloro-2-[(*(3S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl) acetic acid

The title compound was prepared by the method of example 1 step (viii) using the product of step (vi).

<sup>1</sup>H NMR DMSO-D<sub>6</sub>: δ 7.79 (2H, d), 7.68 (1H, tt), 7.61 (2H, m), 7.28 (1H, s), 7.27 (1H, dd), 7.22 (1H, d), 3.98 (1H, m), 3.70 (1H, d), 3.65 (1H, d), 3.53 (1H, d), 3.32 (2H, m), 3.06 (1H, dt), 2.56 (1H, d), 2.48 (1H, d), 2.00 (1H, dd), 1.83 (1H, dt), 1.01 (3H, t).

### Examples 10

{4-chloro-2-[(*(3S*)-3-methyl-4-[(4-(trifluoromethyl)phenyl]acetyl]piperazin-1-yl)methyl]phenyl} acetic acid



(i) 5-chloro-2-(2-methoxy-2-oxoethyl)benzoic acid

Sodium formate (0.66 g), diisopropylethyl amine (1.12 ml), acetic anhydride (0.61 ml), and DMF (3.8 ml) were charged to a flask and stirred for 1 h. A solution of the product from example 9 step (iii) (1 g), Pd<sub>2</sub>dba<sub>3</sub> (75 mg) and lithium chloride (412 mg) in DMF (7.6 ml) was added and the reaction was stirred at 80 °C for 16 h. The reaction mixture was cooled  
5 to RT, then diluted with EtOAc and washed with 2M HCl (x 3). The EtOAc layer was dried (Na<sub>2</sub>SO<sub>4</sub>) then concentrated under reduced pressure. The residue was purified by chromatography on silica (eluent EtOAc) to give the sub-title compound as a yellow oil, yield 398 mg

<sup>1</sup>H NMR DMSO-D6: δ 7.88 (1H, d), 7.62 (1H, dd), 7.41 (1H, d), 4.01 (2H, s), 3.58 (3H, s).

10

(ii) methyl [4-chloro-2-(hydroxymethyl)phenyl]acetate

Borane (1.7 ml, 1 M solution in THF) was added dropwise to a solution of the product of step (i) (398 mg) in THF (5 ml) at -0 °C, then allowed to reach RT over 2 h. The reaction mixture was quenched with water, acidified to pH 3 and extracted with EtOAc (x 3). The  
15 combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) then concentrated under reduced pressure. The residue was purified by chromatography on silica (eluent EtOAc) to give the sub-title compound as a yellow oil, yield 335 mg

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.43 (1H, d), 7.25 (1H, dd), 7.17 (1H, d), 4.65 (2H, s), 3.72 (2H, s),  
3.71 (3H, s).

20

(iii) *tert*-butyl (2*S*)-4-[5-chloro-2-(2-methoxy-2-oxoethyl)benzyl]-2-methyl piperazine-1-carboxylate

Methanesulfonyl chloride (1.81 ml) was added to a solution of the product of step (ii) (2.85 g), triethylamine (3.72 ml) in DCM (15 ml) at 0°C. The reaction was stirred for 1 h  
25 at RT, then diluted with. The organic phase was washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) then concentrated under reduced pressure. The residue was purified by chromatography on silica (eluent 1:1 ether/isohexane) to give mesylate as a yellow oil. This mesylate was dissolved in DMF (7 ml) and K<sub>2</sub>CO<sub>3</sub> (0.94 g) followed by the product of example 5 step (iii) (1.37 g) and heated at 75 °C for 4 h. The reaction mixture was allowed to cool to RT,  
30 and partitioned between EtOAc and water. The organic layer was washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) then concentrated under reduced pressure. The residue was purified by

chromatography on silica (eluent 3:7 then 1:1 ether/isohexane) to give the sub-title compound as a yellow oil, yield 1.51 g.

<sup>1</sup>H NMR DMSO-D<sub>6</sub>: δ 7.37 (1H, d), 7.33 (1H, dd), 7.27 (1H, d), 4.09 (1H, m), 3.87 (1.4H, s), 3.67 (1H, d), 3.62 (3H, s), 3.45 (1H, d), 3.35 (1H, d), 3.33 (0.6H, s), 2.89 (1H, dt), 2.58 (2H, m), 2.08 (1H, dd), 1.87 (1H, dt), 1.40 (9H, s), 1.12 (3H, d).

(iv) methyl (4-chloro-2-{{(3S)-3-methylpiperazin-1-yl}methyl}phenyl)acetate TFA salt TFA (10 ml) was added to a solution of the product of step (iii) (1.51 g) in DCM (2 ml) and stirred for 2 h, then concentrated under reduced pressure to give the sub-title compound as an oil, yield- quantatative.

MS: ESI(+ve) 297(M+H)

(v) {4-chloro-2-[(3S)-3-methyl-4-[(4-(trifluoromethyl)phenyl]acetyl]piperazin-1-yl)methyl]phenyl}acetic acid  
DMF (1 drop) was added to a solution of oxalyl chloride (2 equivalents), [4-(trifluoromethyl)phenyl]acetic acid (0.14 g) in DCM and stirred for 1 h, then the solvents were removed under reduced pressure. The residue was dissolved in DCM (1 ml) and added dropwise to a vigorously stirred solution of the product of step (iv) (0.25 g), DCM (3 ml) and 3M aqueous K<sub>2</sub>CO<sub>3</sub> (2 ml). The reaction was stirred for 2 days, then diluted with DCM (3ml) and water. The organic phase was separated, washed (1M NaOH) and then concentrated under reduced pressure [MS: ESI(+ve) 483 (M+H)]. The residue was dissolved in THF (1 ml). 4N NaOH (1 ml) was added and the mixture was stirred vigorously for 4 h, then cooled to 0 °C and acidified with concentrated HCl (0.6 ml). The product was extracted with EtOAc and the organic phase was concentrated under reduced pressure, then purified by RPHPLC to give the title compound was a white solid.


<sup>1</sup>H NMR DMSO-D<sub>6</sub>: δ 7.66 (2H, d), 7.47 (2H, d), 7.36 (1H, s), 7.27 (2H, m), 4.43 (1H, s), 3.96 (1H, s), 3.85 (1H, d), 3.79 (1H, d), 3.76 (1H, d), 3.70 (1H, d), 3.52 (1H, s), 3.44 (1H, d), 3.08 (1H, m), 2.73 (1H, d), 2.63 (1H, td), 2.14 (1H, dd), 1.95 (1H, td), 1.20 (3H, d).

MS: APCI(-ve) 435(M-H)

Examples 11-14 were synthesised by the method of example 10 step (v) using the product of example 10 step (v) and the appropriate acid or sulfonyl chloride.

## Example 11

[4-chloro-2-{(3*S*)-4-[(4-methoxyphenyl)acetyl]-3-methylpiperazin-1-yl}methyl]phenyl]acetic acid




5  $^1\text{H}$  NMR DMSO-D6:  $\delta$  7.36 (1H, s), 7.27 (2H, s), 7.16 (2H, d), 6.88 (2H, d), 4.41 (1H, s), 3.95 (1H, s), 3.77 (3H, s), 3.74 (2H, s), 3.65 (1H, d), 3.59 (1H, d), 3.48 (1H, d), 3.42 (1H, d), 3.02 (1H, t), 2.70 (1H, d), 2.61 (1H, d), 2.10 (1H, d), 1.91 (1H, t), 1.16 (3H, d).

MS: APCI(-ve) 429(M-H)

## 10 Example 12

[4-chloro-2-{(3*S*)-4-[(2,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl]phenyl]acetic acid




15  $^1\text{H}$  NMR DMSO-D6:  $\delta$  7.38 (1H, s), 7.36 - 7.26 (3H, m), 7.09 (1H, dt), 7.00 (1H, tdd), 4.41 (1H, s), 3.96 (1H, m), 3.79 (1H, d), 3.73 (1H, d), 3.69 (2H, s), 3.51 (1H, d), 3.45 (1H, d), 3.10 (1H, m), 2.74 (1H, d), 2.65 (1H, td), 2.18 (1H, dd), 1.99 (1H, td), 1.23 (3H, d).

MS: APCI(-ve) 435(M-H)

## 20 Example 13

[4-chloro-2-{(3*S*)-4-[(3,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl]phenyl]acetic acid




<sup>1</sup>H NMR DMSO-D6: δ 7.37 (1H, s), 7.33 - 7.22 (4H, m), 7.08 (1H, m), 4.41 (1H, s), 3.96 (1H, s), 3.78 (1H, d), 3.72 (1H, d), 3.74 (1H, d), 3.68 (1H, d), 3.49 (1H, d), 3.43 (1H, d), 3.05 (1H, t), 2.72 (1H, d), 2.63 (1H, td), 2.13 (1H, dd), 1.94 (1H, td), 1.19 (3H, d).  
MS: APCI(-ve) 435(M-H)

5

#### Example 14


(2-{[(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl}-4-chlorophenyl) acetic acid



<sup>1</sup>H NMR DMSO-D6: δ 7.46 - 7.33 (6H, m), 7.27 (2H, m), 4.39 (1H, d), 4.33 (1H, d), 3.83 (1H, m), 3.76 (1H, d), 3.70 (1H, d), 3.47 (1H, d), 3.42 (1H, d), 3.32 (1H, dt), 3.13 (1H, td), 2.60 (1H, d), 2.51 (1H, m), 2.17 (1H, dd), 2.00 (1H, td), 1.22 (3H, d).  
MS: APCI(-ve) 435(M-H)

#### Example 15

15 [4-chloro-2-({(3*S*)-4-[(4-chlorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl)phenyl]acetic acid



(i) *tert*-butyl (3*S*)-4-[(4-chlorophenyl)acetyl]-3-methylpiperazine-1-carboxylate

The sub-title compound was prepared by the method of example 4 step (i) using the

20 product of example 2 step (i) and (4-chloro)phenylacetyl chloride.

<sup>1</sup>H NMR CDCl<sub>3</sub>: δ 7.3 (2H, d), 7.22-7.13 (2H, m), 4.85-4.36 (1H, m), 4.08-3.15 (6H, m), 3.01-2.55 (2H, m), 1.45 (9H, s), 1.13 (3H, d).

(ii) [4-chloro-2-((3*S*)-4-[(4-chlorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid

The mesylate from example 10 step (ii) (300 mg), the product of step (i) (275 mg), K<sub>2</sub>CO<sub>3</sub> (256 mg) and DMF (3 ml) were charged to a flask, then heated at 60 °C for 3 h. The reaction was allowed to cool to RT and partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried (MgSO<sub>4</sub>) and concentrated under reduced pressure. The residue was purified by SCX (eluent EtOAc, MeCN, MeOH then NH<sub>3</sub> in MeOH). The product containing fractions were concentrated under reduced pressure and the residue was purified by chromatography on silica (eluent ether) to give the sub-title compound as a yellow oil, yield 1.51 g.

MS: ESI(+ve) 449(M+H)

(iii) [4-chloro-2-((3*S*)-4-[(4-chlorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid


The product from step (ii) was dissolved in a mixture of THF (3 ml) and 25 % NaOH (3 ml), then stirred for 1 h at 50 °C. The reaction mixture was cooled to RT, acidified with acetic acid (10 ml) and then concentrated under reduced pressure. The residue was purified by RPHPLC to give the title compound, yield 90 mg.

<sup>1</sup>H NMR DMSO-D6: δ 7.31 (3H, m), 7.24 (4H, m), 4.37 (1H, s), 3.90 (1H, s), 3.72 (1H, d), 3.69 (1H, d), 3.66 (1H, d), 3.63 (1H, d), 3.45 (1H, d), 3.39 (1H, d), 3.01 (1H, m), 2.67 (1H, d), 2.58 (1H, d), 2.08 (1H, dd), 1.89 (1H, td), 1.14 (3H, d).

MS: APCI(-ve) 433 (M-H)

### Example 16

(4-chloro-2-[(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl]methyl)phenyl]acetic acid



(i) methyl (4-chloro-2-{{(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl}methyl}phenyl)acetate

HATU (0.28 g) was added to a stirred solution of the product of example 10 step (iv) (100 mg), phenyl acetic acid (102 mg), hunigs base (0.26 ml), DCM (2 ml) and NMP (2 ml).

5 The reaction was stirred for 2 h, then diluted with water, extracted with EtOAc (x 2). The combined organic extracts were washed with aqueous NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>) and then concentrated under reduced pressure. The residue was purified by chromatography on silica (eluent 8:2 ether/ isohexane) to give the sub-title compound – used crude  
MS: ESI(+ve) 415(M+H)


10

(ii) (4-chloro-2-{{(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl}methyl} phenyl)acetic acid  
The title compound was prepared by the method of example 1 (viii) using the product of step (i).

<sup>1</sup>H NMR DMSO-D6: δ 7.30 - 7.16 (8H, m), 4.38 (1H, s), 4.05 - 3.38 (7H, m), 3.01 (1H, s),  
15 2.68 (1H, d), 2.57 (1H, d), 2.06 (1H, dd), 1.89 (1H, m), 1.13 (3H, d).  
MS: APCI(-ve) 401(M-H)

### Example 17

[4-chloro-2-({(3*S*)-4-[{(4-fluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl}phenyl]acetic acid



(i) methyl [4-chloro-2-({(3*S*)-4-[{(4-fluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl}phenyl]acetate

The sub-title compound was prepared by the method of example 16 step (i) using the

25 product of example 10 step (iv).

(ii) [4-chloro-2-({(3*S*)-4-[{(4-fluorophenyl)acetyl]-3-methylpiperazin-1-yl}methyl}phenyl]acetic acid


The title compound was prepared by the method of example 1 (viii) using the product of step (i).

<sup>1</sup>H NMR DMSO-D<sub>6</sub>: δ 7.29 - 6.95 (7H, m), 4.36 (1H, s), 4.03 - 3.22 (7H, m), 3.04 (1H, s), 2.71 (1H, d), 2.59 (1H, d), 2.06 (1H, dd), 1.90 (1H, td), 1.15 (3H, d).

5 MS: APCI(-ve) 419(M-H)

### Example 18

[4-chloro-2-((3*S*)-3-ethyl-4-[(4-fluorophenyl)acetyl]piperazin-1-yl)methyl] phenyl]acetic acid



10

i) (3*S*)-3-Ethyl-1-(phenylmethyl)-2,5-piperazinedione

To a solution of DCC (5.07 g) in DCM (140 ml) at 0 °C was added *N*-BOC-L-α-aminobutyric acid (5 g) followed by ethyl *N*-benzylglycinate (4.6 mL) dropwise. The resulting solution was stirred at 0 °C for 2 h and then at RT 1 h, filtered and the 15 concentrated to give an oil. This was dissolved in DCM (100 mL) and TFA (100 ml) and stirred for 1 h. The solution was concentrated under reduced pressure. The residue was stirred in saturated aq NaHCO<sub>3</sub> (125 ml) and EtOAc (125 ml) for 6 h. The organics were separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to give the sub-title compound as a white solid. (5.68 g).

20 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.37 - 7.31 (3H, m), 7.26 (2H, m), 6.80 (1H, s), 4.70 (1H, d), 4.50 (1H, d), 4.05 (1H, s), 3.87 (1H, d), 3.80 (1H, d), 1.93 (2H, m), 0.98 (3H, t).

ii) (3*S*)-3-Ethyl-1-(phenylmethyl)-piperazine

To a solution of the product of example 69 part a) (5.68 g) in THF (30 ml) at 0 °C was 25 added LAH (100 ml, 1.0M in THF) dropwise. The resulting solution was heated at reflux overnight. The reaction mixture was cooled to RT and quenched by cautious sequential addition of water (3.8 ml), 15% aq NaOH (3.8 ml), and water (11.4 ml). The precipitous solution was diluted with EtOAc and filtered through Celite. The residue was washed with

EtOAc (3 x 100 ml) and the combined organics concentrated *in vacuo*. The crude product was dissolved in DCM, filtered through Celite and the solvent removed in vacuo to give the sub-title product as a yellow oil (4.74 g).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.41 - 7.19 (5H, m), 3.53 (1H, d), 3.46 (1H, d), 2.99 - 2.61 (5H, m),  
5 2.01 (1H, dt), 1.69 (1H, t), 1.35 (2H, dquin), 0.90 (3H, t).

iii) (2S)-2-Ethyl-4-(phenylmethyl)-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester

To a solution of the product from example 69 part b) (4.74 g) in DCM (150 ml) was added (BOC)<sub>2</sub>O (5.52 g) and the reaction stirred at RT for 48 h. The reaction was concentrated  
10 under reduced pressure. The crude product was purified by chromatography (silica, (0-  
10% EtOAc/isohexane as eluent)), to give the sub-titled compound as a colourless oil  
(6.09g).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.33 - 7.22 (5H, m), 3.89 (2H, m), 3.53 (1H, d), 3.38 (1H, d), 3.04  
15 (1H, t), 2.71 (2H, dd), 2.02 (2H, ddd), 1.83 (1H, m), 1.64 (1H, m), 1.45 (9H, s), 0.80 (3H,  
t).

iv) (2S)-2-Ethyl-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester

A solution of the product from example 69 part c) (6.09 g) and 10% Pd/C (1.14 g) in EtOH  
(85 mL) was hydrogenated at 3.8 bar for 16 h. The reaction mixture was filtered through  
20 Celite and the filtrate concentrated *in vacuo* to give the sub-title compound as an oil (3.65  
g).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.87 (2H, m), 2.87 (4H, m), 2.68 (1H, td), 1.76 (1H, m), 1.59 (1H, m),  
1.46 (9H, s), 0.89 (3H, t).

25 v) *tert*-butyl (2S)-4-[5-chloro-2-(2-methoxy-2-oxoethyl)benzyl]-2-ethylpiperazine-1-  
carboxylate

The sub-title eompound was prepared by the method of example 10 step (iii) using the  
products of example 10 step (ii) and the product of step (iv).

<sup>1</sup>H NMR DMSO-D6: δ 7.33 (1H, d), 7.30 (1H, dd), 7.25 (1H, d), 3.83 (2H, s), 3.71 (1H,  
30 d), 3.60 (3H, s), 3.42 (1H, d), 3.31 (1H, m), 2.81 (2H, m), 2.63 (1H, d), 2.57 (1H, d), 1.99  
(1H, dd), 1.85 (1H, td), 1.63 (1H, m), 1.53 (1H, m), 1.38 (9H, s), 0.73 (3H, t).

vi) methyl (4-chloro-2-[(*(3S*)-3-ethylpiperazin-1-yl]methyl)phenyl)acetate trifluoroacetate  
The sub-title compound was prepared by the method of example 10 step (iv) using the product of step (v).

5 vii) [4-chloro-2-((*(3S*)-3-ethyl-4-[(4-fluorophenyl)acetyl]piperazin-1-yl)methyl)phenyl]acetic acid


The title compound was prepared by the method of example 2 step (ii) and the method of example 1 step (viii) using the product of step (vi) and 4-fluorophenylacetyl chloride.

<sup>1</sup>H NMR DMSO-D6 (90 °C) : δ 7.35 (1H, s), 7.27 (4H, m), 7.11 (2H, t), 4.06 (2H, m), 3.78  
10 - 3.64 (4H, m), 3.47 (1H, d), 3.42 (1H, d), 3.00 (1H, s), 2.71 (2H, m), 2.02 (1H, dd), 1.92  
(1H, td), 1.67 (2H, m), 0.74 (3H, t).

MS: APCI(-ve) 431(M-H)

#### Example 19

15 [4-chloro-2-((*(3S*)-4-[(4-chlorophenyl)acetyl]-3-ethylpiperazin-1-yl)methyl)phenyl]acetic acid



The title compound was prepared by the method of example 2 step (ii) and the method of example 1 step (viii) using the product of step example 18 step (vi) and 4-chlorophenylacetyl chloride.


<sup>1</sup>H NMR DMSO-D6 (90 °C) : δ 7.39 - 7.20 (7H, m), 3.89 - 2.84 (5H, m), 3.75 (1H, d),  
3.67 (1H, d), 3.64 (1H, d), 3.58 (1H, d), 2.73 (2H, d), 2.02 (1H, dd), 1.96 (1H, dd), 1.69  
(2H, m), 0.75 (3H, t).

MS: APCI(-ve) 447(M-H)

25

#### Example 20

2-(2-((*(3S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl)methyl)-4-chlorophenyl)-N-(methylsulfonyl)acetamide



The product of example 15 step (iii) (50 mg) was taken up in DCM (1 ml) and methane sulfonamide (13 mg) and PyBOP (89 mg) added followed by Hunigs base (0.06 ml). The mixture was stirred at room temperature for 16 h then evaporated under reduced pressure  
5 and the residue purified by RPHPLC. The resulting fractions were evaporated under reduced pressure and passed through an SCX resin (eluting with methanol then 7N ammonia in methanol). The basic fractions were evaporated under reduced pressure to give a white solid (13 mg).

<sup>1</sup>H NMR DMSO-D<sub>6</sub>: δ 7.42-7.34 (5H, m), 7.31 (1H, d), 7.24 (1H, dd), 7.19 (1H, d) 4.41  
10 (1H, d), 4.35 (1H, d), 3.77 (1H, m), 3.62 (1H, d), 3.53 (1H, d), 3.41 (2H, s), 3.12 (2H, m),  
2.94 (3H, s), 2.60 (1H, d), 2.46 (1H, d), 2.07 (1H, dd), 1.95 (1H, dt), 1.18 (3H, d).  
MS: APCI(+ve) 514 (M+H).

### Pharmacological Data

#### Ligand Binding Assay

[<sup>3</sup>H]PGD<sub>2</sub> was purchased from Perkin Elmer Life Sciences with a specific activity of 100-210Ci/mmol. All other chemicals were of analytical grade.

5 HEK cells expressing rhCRTh2 / Gα16 were routinely maintained in DMEM containing 10% Foetal Bovine Serum (HyClone), 1mg/ml geneticin, 2mM L-glutamine and 1% non-essential amino acids. For the preparation of membranes, the adherent transfected HEKcells were grown to confluence in two layer tissue culture factories (Fisher, catalogue number TKT-170-070E). Maximal levels of receptor expression were  
10 induced by addition of 500mM sodium butyrate for the last 18 h of culture. The adherent cells were washed once with phosphate buffered saline (PBS, 50ml per cell factory) and detached by the addition of 50ml per cell factory of ice-cold membrane homogenisation buffer [20mM HEPES (pH 7.4), 0.1mM dithiothreitol, 1mM EDTA, 0.1mM phenyl methyl sulphonyl fluoride and 100μg/ml bacitracin]. Cells were pelleted by centrifugation at  
15 220xg for 10 minutes at 4°C, re-suspended in half the original volume of fresh membrane homogenisation buffer and disrupted using a Polytron homogeniser for 2 x 20 second bursts keeping the tube in ice at all times. Unbroken cells were removed by centrifugation at 220xg for 10 minutes at 4°C and the membrane fraction pelleted by centrifugation at 90000xg for 30 minutes at 4°C. The final pellet was re-suspended in 4 ml of membrane  
20 homogenisation buffer per cell factory used and the protein content determined.

Membranes were stored at -80°C in suitable aliquots.

All assays were performed in Corning clear bottomed, white 96-well NBS plates (Fisher). Prior to assay, the HEK cells membranes containing CRTh2 were coated onto SPA PVT WGA beads (Amersham). For coating membranes were incubated with beads at  
25 typically 25μg membrane protein per mg beads at 4°C with constant agitation overnight. (The optimum coating concentrations were determined for each batch of membranes) The beads were pelleted by centrifugation (800xg for 7minutes at 4°C), washed once with assay buffer (50mM HEPES pH 7.4 containing 5mM magnesium chloride) and finally re-suspended in assay buffer at a bead concentration of 10mg/ml.


30 Each assay contained 20μl of 6.25nM [<sup>3</sup>H]PGD<sub>2</sub>, 20μl membrane saturated SPA beads both in assay buffer and 10μl of compound solution or 13,14-dihydro-15-keto prostaglandin D<sub>2</sub> (DK-PGD<sub>2</sub>, for determination of non-specific binding, Cayman chemical

company). Compounds and DK-PGD<sub>2</sub> were dissolved in DMSO and diluted in the same solvent to 100x the required final concentration. Assay buffer was added to give a final concentration of 10% DMSO (compounds were now at 10x the required final concentration) and this was the solution added to the assay plate. The assay plate was 5 incubated at RT for 2 h and counted on a Wallac Microbeta liquid scintillation counter (1 minute per well).

Compounds of formula (I) have an IC<sub>50</sub> value of less than (<) 10μM. Specifically Example 4 has a pIC<sub>50</sub> value of 7.1, example 9 has a pIC<sub>50</sub> value of 7.85, example 12 has a pIC<sub>50</sub> value of 8.1.

## CLAIMS

1. A compound of formula (I) or a carboxylic acid bioisostere thereof:



(I)

in which:

V is CR<sup>1</sup>R<sup>2</sup>, CR<sup>1</sup>R<sup>2</sup>-CR<sup>1</sup>R<sup>2</sup> or V is S(O)<sub>n</sub>CR<sup>1</sup>R<sup>2</sup> (where n is 0, 1 or 2), NR<sup>11</sup>CR<sup>1</sup>R<sup>2</sup>,  
 10 CCR<sup>1</sup>R<sup>2</sup>, CR<sup>1</sup>R<sup>2</sup>C or CR<sup>1</sup>CR<sup>2</sup>;

R<sup>1</sup> and R<sup>2</sup> independently represent a hydrogen atom, halogen, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or a C<sub>1-6</sub>alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, NR<sup>9</sup>R<sup>10</sup>, OR<sup>8</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2);  
 15 or

R<sup>1</sup> and R<sup>2</sup> together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR<sup>11</sup> and itself optionally substituted by one or more C<sub>1</sub>-C<sub>3</sub> alkyl or halogen;


W is hydrogen, halogen, cyano, nitro, SO<sub>2</sub>R<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, OR<sup>8</sup>, or C<sub>1-6</sub>alkyl, the latter being optionally substituted by one or more substituents independently selected from halogen, OR<sup>8</sup> and NR<sup>7</sup>R<sup>8</sup>, S(O)<sub>n</sub>R<sup>5</sup> where n is 0, 1 or 2.  
 20

R<sup>3</sup> is one or more substituents independently selected from hydrogen, halogen, CN, nitro, SO<sub>2</sub>R<sup>7</sup>, OR<sup>8</sup>, SR<sup>7</sup>, SOR<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, CONR<sup>9</sup>R<sup>10</sup>, NR<sup>9</sup>R<sup>10</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>7</sup>, NR<sup>11</sup>CO<sub>2</sub>R<sup>7</sup>, NR<sup>11</sup>COR<sup>7</sup> or C<sub>1-6</sub>alkyl, the latter being optionally substituted by one or more substituents independently selected from halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> where n is 0, 1 or 2;  
 25

X represents a bond, or C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted by one or more substituents independently selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl the latter being optionally

substituted by one or more substituents independently selected from halogen, OR<sup>6</sup> and NR<sup>7</sup>R<sup>8</sup>, S(O)<sub>n</sub>R<sup>5</sup> where n is 0, 1 or 2;

Y represents a diamine of the following type:-



R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen, SO<sub>2</sub>R<sup>7</sup>, C(O)R<sup>7</sup>, CO<sub>2</sub>R<sup>7</sup> and C<sub>1</sub>-C<sub>6</sub> alkyl, the latter being optionally substituted by one or more substituents independently selected from aryl, heteroaryl, halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> where n is 0, 1 or 2;

10 R<sup>4</sup> and R<sup>5</sup> are joined together or one of R<sup>4</sup> and R<sup>5</sup> is joined onto P or Q to form a saturated heterocyclic 3-10 membered ring with, 1 or 2 endocyclic nitrogen atoms;

P and Q independently represent, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by one or more substituents independently selected from (=O), halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2), C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl or heteroaryl (the latter two being 15 optionally substituted by one or more substituents independently selected from halogen, OR<sup>8</sup> and NR<sup>9</sup>R<sup>10</sup>, CONR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> where n is 0, 1 or 2);

Z represents a bond, (CR<sup>12</sup>)n-C(O), (CR<sup>12</sup>)n-S(O)n, C(O)(CR<sup>12</sup>)n, or S(O)<sub>2</sub>(CR<sup>12</sup>)n, S(O)<sub>2</sub>N(CR<sup>12</sup>)n, where n= 0, 1 or 2;.

HET represents aryl or heteroaryl;

20 R<sup>6</sup> represents one or more substituents independently selected from hydrogen, halogen, CN, nitro, COR<sup>7</sup>, CO<sub>2</sub>R<sup>8</sup>, SO<sub>2</sub>R<sup>7</sup>, OR<sup>8</sup>, SR<sup>8</sup>, SOR<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, CONR<sup>9</sup>R<sup>10</sup>, NR<sup>9</sup>R<sup>10</sup>, NR<sup>8</sup>SO<sub>2</sub>R<sup>7</sup>, NR<sup>8</sup>CO<sub>2</sub>R<sup>8</sup>, NR<sup>8</sup>COR<sup>7</sup>, NR<sup>8</sup>CONR<sup>9</sup>R<sup>10</sup>, NR<sup>8</sup>SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, aryl, heteroaryl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1</sub>-alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, 25 C<sub>3</sub>-C<sub>7</sub> cycloalkyl, CN, OR<sup>8</sup>, NR<sup>9</sup>R<sup>10</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2), CONR<sup>9</sup>R<sup>10</sup>, NR<sup>8</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup> and NR<sup>8</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>7</sup> represents a C<sub>1</sub>-C<sub>6</sub> alkyl, an aryl or a heteroaryl group all of which may be optionally substituted by halogen atoms, OR<sup>8</sup>, NR<sup>14</sup>R<sup>15</sup>;

30 R<sup>8</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, an aryl or a heteroaryl group all of which may be optionally substituted by halogen atoms, OR<sup>8</sup>, NR<sup>14</sup>R<sup>15</sup>;

$R^9$  and  $R^{10}$  independently represent hydrogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup> and NR<sup>14</sup>R<sup>15</sup>, S(O)<sub>n</sub>R<sup>6</sup> (where n = 0,1 or 2), CONR<sup>7</sup>R<sup>8</sup>, NR<sup>6</sup>COR<sup>7</sup>,SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>5</sup>;

5           or

$R^9$  and  $R^{10}$  together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)<sub>n</sub> (where n = 0,1 or 2), NR<sup>13</sup>, and itself optionally substituted by halogen or C<sub>1-3</sub> alkyl;

10           $R^{11}$  represents a hydrogen atom, C(O)R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl an aryl or a heteroaryl group (the latter three can be optionally substituted by halogen);

12           $R^{12}$  represents one or more from hydrogen, or a C<sub>1-6</sub>alkyl group, the latter being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, NR<sup>14</sup>R<sup>15</sup>, OR<sup>8</sup>, S(O)<sub>n</sub>R<sup>7</sup> (where n is 0, 1 or 2);

15           $R^{13}$  represent hydrogen, C<sub>1-4</sub> alkyl, -COC<sub>1</sub>-C<sub>4</sub> alkyl, COYC<sub>1</sub>-C<sub>4</sub>alkyl where Y is O or NR<sup>7</sup>; and

$R^{14}$  and  $R^{15}$  independently represent hydrogen, C<sub>1-4</sub> alkyl  
or

14           $R^{14}$  and  $R^{15}$  together with the nitrogen atom to which they are attached can form a  
20 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)<sub>n</sub> (where n = 0,1 or 2), NR<sup>13</sup>, and itself optionally substituted by halogen or C<sub>1-3</sub> alkyl;

and pharmaceutically acceptable salts thereof.

25 2.       A compound according to claim 1 in which V is CR<sup>1</sup>R<sup>2</sup>, CR<sup>1</sup>R<sup>2</sup>-CR<sup>1</sup>R<sup>2</sup>, CCR<sup>1</sup>R<sup>2</sup> or CR<sup>1</sup>R<sup>2</sup>C.

3.       A compound according to claim 1 or 2 in which W is hydrogen, halogen or CF<sub>3</sub>.

30 4.       A compound according to any one of claims 1 to 3 in which R<sup>1</sup> and R<sup>2</sup> are hydrogen.


5. A compound according to any one of claims 1 to 4 in which R<sup>3</sup> is hydrogen.

6. A compound according to any one of claims 1 to 5 in which X is CH<sub>2</sub>;


5 7. A compound according to any one of claims 1 to 6 in which the group Z is SO<sub>2</sub>,  
SO<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>.

8. A compound according to any one of claims 1 to 7 in which the group Y together  
with the 2 nitrogen atoms it is attached forms a 4-7 membered saturated ring, optionally  
10 substituted by C<sub>1-4</sub> alkyl.


9. A compound according to any one of claims 1 to 8 in which the carboxylic acid  
bioisostere is a group of formula (XI) to (XV):




(XI)




(XII)



(XIII)



(XIV)



(XV)

15

10. A compound of formula (I) according to any one of claims 1 to 5 selected from:  
Sodium 3-(2-{{[4-(benzylsulfonyl)piperazin-1-yl]methyl}-4-chlorophenyl) propanoate;  
20 3-(2-{{[(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl}-4-chlorophenyl) propanoic  
acid;  
Sodium 3-(4-chloro-2-{{[(3*S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-  
yl]methyl}phenyl)propanoate;  
3-(4-chloro-2-{{[(3*S*)-3-methyl-4-(phenylacetyl)piperazin-1-yl]methyl}phenyl) propanoic  
25 acid;  
3-[4-chloro-2-({{(3*S*)-3-methyl-4-[(4-methylbenzyl)sulfonyl]piperazin-1-yl)methyl}  
phenyl]propanoic acid;  
3-[4-chloro-2-({{(3*S*)-3-methyl-4-[(3-methylbenzyl)sulfonyl]piperazin-1-  
yl)methyl}phenyl]propanoic acid;

3-[4-chloro-2-((3*S*)-3-methyl-4-[(2-methylbenzyl)sulfonyl]piperazin-1-yl)methyl]phenyl]propanoic acid;

(2-[(3*S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl)acetic acid;

(4-chloro-2-[(3*S*)-3-methyl-4-(phenylsulfonyl)piperazin-1-yl]methyl)phenyl)acetic acid;

5 {4-chloro-2-[(3*S*)-3-methyl-4-[(4-(trifluoromethyl)phenyl)acetyl]piperazin-1-yl)methyl]phenyl}acetic acid;

[4-chloro-2-((3*S*)-4-[(4-methoxyphenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid;

[4-chloro-2-((3*S*)-4-[(2,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid;

10 [4-chloro-2-((3*S*)-4-[(3,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid;

[4-chloro-2-((3*S*)-4-[(3,4-difluorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid;

(2-[(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl)-4-chlorophenyl) acetic acid;

[4-chloro-2-((3*S*)-4-[(4-chlorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid;

15 [4-chloro-2-((3*S*)-3-ethyl-4-[(4-fluorophenyl)acetyl]piperazin-1-yl)methyl]phenyl]acetic acid;

[4-chloro-2-((3*S*)-4-[(4-fluorophenyl)acetyl]-3-methylpiperazin-1-yl)methyl]phenyl]acetic acid;

[4-chloro-2-((3*S*)-3-ethyl-4-[(4-fluorophenyl)acetyl]piperazin-1-yl)methyl]phenyl]acetic acid;

20 [4-chloro-2-((3*S*)-4-[(4-chlorophenyl)acetyl]-3-ethylpiperazin-1-yl)methyl]phenyl]acetic acid;

[4-chloro-2-((3*S*)-4-[(4-chlorophenyl)acetyl]-3-ethylpiperazin-1-yl)methyl]phenyl]acetic acid;

25 2-(2-[(3*S*)-4-(benzylsulfonyl)-3-methylpiperazin-1-yl]methyl)-4-chlorophenyl-N-(methylsulfonyl)acetamide

and pharmaceutically acceptable salts thereof.

11. A compound of formula (I) according to any one of claims 1 to 10 for use in therapy.

30 12. A method of treating a disease mediated by prostaglandins, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claims 1 to 10.

13. A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claims 1 to 10.

5

14. A method of treating a respiratory disease, such as asthma and rhinitis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in claims 1 to 10.

10

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
10 May 2007 (10.05.2007)

PCT

(10) International Publication Number  
**WO 2007/052023 A3**(51) International Patent Classification:  
*C07D 295/18* (2006.01)    *A6IK 3I/4965* (2006.01)  
*C07D 295/22* (2006.01)    *A6IP 11/00* (2006.01)

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(21) International Application Number:  
PCT/GB2006/004075(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(22) International Filing Date:  
1 November 2006 (01.11.2006)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).(30) Priority Data:  
0522619.6                5 November 2005 (05.11.2005)    GB  
0607353.0                12 April 2006 (12.04.2006)    GB**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC only*): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (*for MG only*): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): LUKER, Timothy [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

WO 2007/052023 A3

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/004075

## A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D295/18 C07D295/22 A61K31/4965 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MANOURY P M ET AL: "Synthesis and Analgesic Activities of Some (4-Substituted Phenyl-1-Piperazinyl)alkyl 2-Aminobenzoates and 2-Aminonicotinates" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 22, no. 5, 1979, pages 554-559, XP002347769 ISSN: 0022-2623 Discussion page 556; table IV -----	1
A	EP 1 170 594 A (PFIZER PROD INC [US]) 9 January 2002 (2002-01-09) cited in the application claims 1-18; figures 10A,10B -----	1-14



Further documents are listed in the continuation of Box C.



See patent family annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

28 August 2007

Date of mailing of the international search report

06/09/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Goss, Ilaria

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2006/004075

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 12 to 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/GB2006/004075

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 1170594	A 09-01-2002	JP 2002098702 A	JP 2004004109 A	05-04-2002 08-01-2004